Agenus Reports Landmark Three-Year Survival Data for BOT+BAL in Metastatic Colorectal Cancer

Agenus Inc. announced three-year landmark Phase 1b data for its combination therapy of botensilimab (BOT) and balstilimab (BAL) in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data, presented at ESMO GI 2026, showed a 33% three-year overall survival rate and a median overall survival of 21.2 months in a heavily pretreated patient population. This represents a clinically meaningful long-term survival benefit in a setting where conventional immune checkpoint inhibitors have historically offered limited benefit.

Context

Metastatic colorectal cancer, particularly in patients with microsatellite-stable tumors, has been difficult to treat effectively with existing therapies. Traditional immune checkpoint inhibitors have shown limited efficacy in this group. Agenus' Phase 1b study results provide new insights into potential treatment alternatives.

Why it matters

The announcement of three-year survival data for Agenus' combination therapy is significant as it offers hope for patients with a challenging form of metastatic colorectal cancer. This patient population has limited treatment options, making any improvement in survival rates noteworthy. The findings may influence future treatment protocols and research directions in oncology.

Implications

If the combination therapy is validated in larger studies, it could change treatment standards for refractory MSS metastatic colorectal cancer. Patients may gain access to a new therapeutic option that could extend survival. The results may also prompt further investment in similar combination therapies for other cancer types.

What to watch

Upcoming clinical trials may further explore the efficacy and safety of the BOT and BAL combination in larger patient populations. Regulatory responses to the data could shape the availability of this therapy. Additionally, reactions from the medical community and patient advocacy groups will be important to monitor.